Biopharmaceuticals
- Home
- Biopharmaceuticals
Public
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Novatti launches new payments platform for purpose-issued Visa cards
- Review
- September 29, 2020
Latest Articles
Pharmaxis targeting scar-free recovery from burns with world-first trials
One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS). The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play
Read MorePublic
Zoono secures Chinese distributor after impressive African swine fever trials
With China having lost more than 100 million pigs due to the recent outbreak of African swine fever in the mainland, attention has been thrust upon preventative measures, leading a Chinese Group to engage chemical company Zoono (ASX: ZNO) for a 10-year distribution arrangement. The Chinese Group will use the Zoono China brand to sell
Read MorePublic
Neuren secures European patent for drug aimed to treat incurable brain disorders
Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. The granting of the new patent is the third jurisdiction to do so for Neuren with the same application
Read MorePublic
MGC Pharma doubles cannabinoid prescriptions in one month
Biopharmaceuticals manufacturer MGC Pharmaceuticals (ASX: MXC) has seen significant uptake of its cannabinoid medications with prescriptions across Australia and the United Kingdom doubling to 800 patients through the month of October. The update comes as more medical practitioners prescribe phytocannabinoid-derived medications CannEpil®, which targets drug-resistant epilepsy, and MXP100 which is recommended for neurological disorders, inflammation
Read MorePublic